Intravitreal bevacizumab for age-related macular degeneration with good visual acuity.

To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA).
Fifteen eyes of 15 patients (mean age, 69.0 ± 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 ± 4.9 months).
Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 ± 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 ± 71.9 μm at baseline to 240.00 ± 58.5 μm at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed.
IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months.
AuthorsMaki Takahashi, Taku Sato, Shoji Kishi
JournalJapanese journal of ophthalmology (Jpn J Ophthalmol) Vol. 54 Issue 6 Pg. 565-70 (Nov 2010) ISSN: 1613-2246 [Electronic] Japan
PMID21191717 (Publication Type: Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization (diagnosis, drug therapy, physiopathology)
  • Exudates and Transudates
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Humans
  • Intravitreal Injections
  • Macular Degeneration (diagnosis, drug therapy, physiopathology)
  • Male
  • Middle Aged
  • Photochemotherapy
  • Retreatment
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: